Lumifil is a series of cross-linked hyaluronic acid fillers with lidocaine: 20 mg/mL hyaluronic acid and 3 mg/mL lidocaine hydrochloride. The series consists of L-Lite, L-Kiss and L-Max and is manufactured by BNC Korea. BC Nordic is the exclusive distributor of Lumifil in the Nordics and delivers to verified clinics.
CE-marked medical device. For authorised healthcare professionals only.
BDDE (1,4-butanediol diglycidyl ether) is a chemical cross-linking agent used to stabilise hyaluronic acid in dermal fillers. According to the manufacturer's instructions for use, Lumifil is cross-linked with BDDE.
Residual amounts of unreacted BDDE may be present after production. The manufacturer's specification for the residual content is at most 2 ppm. In the certificates of analysis from BNC Korea, which we receive for each shipment, BDDE has not been detected.
The certificates are issued by the manufacturer, not by an independent third party, and concern the residual content of unreacted BDDE, not the cross-linked structure.
All three are CE-marked medical devices based on cross-linked hyaluronic acid. Only for patients over 21 years of age, cf. the manufacturer's instructions for use (IFU).
BDDE (1,4-butanediol diglycidyl ether) is used to cross-link the hyaluronic acid in Lumifil, as stated in the manufacturer's instructions for use. Residual amounts of unreacted BDDE may be present after production. The manufacturer's specification for the residual content is at most 2 ppm, and in the certificates of analysis from BNC Korea, BDDE has not been detected. The certificates are issued by the manufacturer, not by an independent third party.
Yes. Lumifil L-Lite, L-Kiss and L-Max are CE-marked medical devices. They are sold to authorised healthcare professionals and registered clinics, not through pharmacies.
BC Nordic is the exclusive distributor of Lumifil in the Nordics and delivers directly to verified clinics in Norway, Denmark, Sweden and Finland, with Norwegian customer service and professional support.
